The creation of retatrutide, a novel dual activator targeting both GLP-1 and GIP receptors, requires a complex several-stage chemical process. Initial routes focused on peptide portion coupling, utilizing solid-phase production methodologies to build the long peptide sequence. Subsequent study ha